Iban Plus Tablet contains Ibandronic Acid 150 mg, a potent bisphosphonate used primarily in the treatment and prevention of osteoporosis in postmenopausal women and other conditions characterized by increased bone resorption. Ibandronic Acid acts by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. It is indicated for patients at high risk of fractures, including those with established osteoporosis or those undergoing long-term corticosteroid therapy. The tablet is administered orally, typically once monthly, to ensure patient compliance and convenience. Iban Plus should be taken with a full glass of water on an empty stomach, at least 60 minutes before the first food, drink, or other medications of the day, and patients should remain upright for at least 30 minutes post-administration to minimize the risk of esophageal irritation. Common adverse effects may include gastrointestinal discomfort, dyspepsia, and musculoskeletal pain. Contraindications include hypocalcemia, esophageal abnormalities, and inability to remain upright. Adequate calcium and vitamin D supplementation is recommended to optimize therapeutic outcomes. Regular monitoring of bone mineral density and renal function is advised during prolonged therapy. Iban Plus Tablet offers an effective option for managing osteoporosis and reducing fracture risk in susceptible populations.